Register by April 11th and Save up to $250! Final Agenda
Optimizing Diagnostics and Therapeutics
May 19-20, 2008 • Hilton Boston Logan Airport • Boston, MA
Sessions Include: Topics:
• Data Analysis • bench to bedside applications
• Models to Predict Responses • response markers
• Stability and Standardization • pathogen surveillance and discovery
• Applied Microarrays • patenting microarray inventions
Molecular Targets & Diagnostics: Critical Role of Sample Preparation in Discovery
James L. Wittliﬀ, Professor of Biochemistry & Molecular Biology, Graham Brown Cancer Center, University of Kentucky
Opportunities and Obstacles in Proteomic Analysis of Bioﬂuids
Sunny Tam, Ph.D., Research Associate Professor, University of Massachusetts Medical School
Cambridge Healthtech Institute
250 First Avenue, Suite 300, Needham, MA 02494
Phone: 781-972-5400 • Fax: 781-972-5425
Toll-free in the U.S. 888-999-6288
MONDAY, MAY 19
7:00 - 6:00 pm Registration Open
7:30 Morning Coﬀee
8:10 Opening Plenary Introduction
8:20 Molecular Targets & Diagnostics: Critical Role of Sample Preparation in Discovery
James L. Wittliff, Professor of Biochemistry & Molecular Biology, Graham Brown Cancer Center, University of Kentucky
9:00 Opportunities and Obstacles in Proteomic Analysis of Bioﬂuids
Sunny Tam, Ph.D., Research Associate Professor, University of Massachusetts Medical School
Proteomic analyses of bioﬂuids, such as plasma or amniotic ﬂuid, traditionally have the same obstacles due to the presence of abundant pro-
teins and large dynamic range of protein concentration. Recent fractionation reagents have helped in the isolation of abundant proteins to allow the
examination of lower abundant proteins. We have examined plasma from a diabetic rat model and important clinical diseases after adequate
fractionation schemes. The proteomic ﬁnding from gel based and iTRAQ based studies have yielded interesting observations after bioinformatics analysis.
Furthermore, the biological signiﬁcances of the diﬀerential protein expression have been validated with traditional biochemical methods.
9:40 Grand Opening Coﬀee Break in the Exhibit Hall Most Gastrointestinal Stromal Tumors (GISTs) contain gain-of-function, i.e., oncogenic mu-
tations in c-KIT or in Platelet Derived Growth Factor Receptor alpha (PDGFRa) and GIST
DATA ANALYSIS patients are treated with imatinib mesylate, originally referred to as STI571 or GleevecTM,
an oral 2-phenylaminopyrimidine derivative that acts as a selective inhibitor against onco-
genic forms of KIT, PDGFa, and BCR-ABL. What is becoming apparent is that clinical man-
10:25 Chairperson’s Remarks agement of GIST may beneﬁt from molecular characterization, i.e., pre-selecting patients
10:30 Microarrays: Bench-to-Bedside for treatment with imatinib or additional ﬁrst and second line therapies based on c-KIT
Towia Libermann , Ph.D., Associate Professor of Medicine, Beth Israel and PDGFRa mutational status or predictive gene signatures. As part of a recent Phase II
Trial of neoadjuvant/adjuvant imatinib for advanced primary and recurrent operable GISTs
Deaconess Medical Center
(RTOG-0132), we used gene proﬁling of pre- and post-imatinib treated biopsies to better
Functional genomics and proteomics approaches have rapidly evolved over the last years
deﬁne prognostic markers. The analysis identiﬁed 38 genes as diﬀerentially expressed in
and have provided the basis for groundbreaking discoveries in basic and clinical research.
pretreatment samples between responders and nonresponders, with all genes present at
As the technologies become more mature and validated, bench-to-bedside clinical applica-
higher levels in nonresponders. Interestingly, seven of these genes mapped to a single
tions rapidly emerge. Our focus has been to identify gene signatures in patients with vari-
locus on chromosome 19p and a subset of these faithfully predicted likely response to
ous types of cancer for early detection, cancer progression, metastasis, survival as well as
imatinib-based therapy in naive panel of GISTs.
resistance or sensitivity to therapy. We have developed novel bioinformatics approaches
for biomarker discovery and individualized gene expression analysis that are enhancing the 2:00 COXEN: Genomic Prediction of Patients’ Responses to
identiﬁcation of aberrant signaling pathways in individual patients and clinical application
of microarray data for patient stratiﬁcation and management. Examples of microarray and
bioinformatics approaches and their potential clinical applications in renal, prostate and Jae Lee, M.D., Associate Professor, Public Health Sciences, University of
breast cancer will be presented together with the implementation of the new fully automa- Virginia School of Medicine
tized Aﬀymetrix platform for high throughput 96 well microarray analysis. The U.S. National Cancer Institute has used a panel of 60 diverse human cancer cell lines
(the NCI-60) to screen >100,000 chemical compounds for anticancer activity. We asked
11:00 Molecular Classiﬁcation of Gliomas: whether it would be possible to identify common chemosensitivity biomarkers from that
Let the Data Inform Treatment rich database to predict drug activity in cell types not included in the NCI-60 panel or,
Jean Claude Zenklusen, Ph.D., Staff Scientist, Neuro-Oncology Branch, even further, clinical responses in patients with tumors. We address that challenge by de-
veloping a novel pharmacogenomic prediction approach “Co-eXpression ExtrapolatioN”
National Institutes of Health, National Cancer Institute
(COXEN), which can eﬀectively identify concordant genomic chemosensitivity biomarkers
Primary brain tumors are the fourth leading cause of cancer mortality in adults under the
between two independent expression proﬁling data sets, here extrapolating the genomic
age of 54 and the leading cause of cancer mortality in children in the United States due
expression patterns of NCI-60 biomarkers with those of clinical tumors. Applying our COX-
to suboptimal therapeutic approaches, hindered by lack of understanding of the biology
EN approach in a prospective fashion, we predicted anticancer drug activities on human
of these tumors. In the framework of the Glioma Molecular Diagnostic Initiative at the
patients in breast, ovarian, bladder cancer, and other types of cancer, who were treated
NCI, we have collected and molecularly characterized (at both RNA and DNA) over 500
with commonly used combination chemotherapeutics. We also used COXEN for in silico
gliomas with corollary clinical data. Here we present a novel, comprehensive, classiﬁca-
screening of 45,545 compounds and identify a novel agent with superior growth inhibition
tion of Gliomas (both high and low grade) based on their mRNA expression proﬁles, which
activity against human bladder cancer.
were analyzed using a variety of class discovery algorithms (HC, K-mean, NMF) without
using any pre-conceived notion of their biological or clinical/histopathological grouping. 2:30 Use of Genomics as a Tool to Identify Stage-Appropriate
The results were validated in a separate datasets (either produced by our own group or
from previously published reports), and classify these tumors into six distinct subclasses
Therapeutic Intervention Strategies
having a nested hierarchy correlating with the tumor’s characteristics from both biological Marti Jett, M.D., Chief, Department of Molecular Pathology, Walter Reed
and clinical standpoints. This novel classiﬁcation along with the wealth of genomic data Army Institute Research
produced by the GMDI may allow for the development of a more rational, objective, diag- Genomic patterns have the potential to reveal the progression of host responses during
nostic of gliomas and serve as an important starting point in the search for new molecular illness and help to pinpoint early indicators of tissue involvement or organ failure. In com-
therapeutic targets. bination with limited proteomics, these ﬁndings can be used to identify markers that will
permit therapeutic eﬀorts to be focused to divert impending serious outcomes. Our stud-
11:30 Microarray Data Analysis ies using a systems approach to integrate clinical, physiological, -omics and mathematical
Yudong He, Ph.D., Scientist, Rosetta Merck modeling have revealed stages of illness progression during which time certain standard
therapies may no longer be eﬀective, yet they also reveal other therapeutic strategies. The
12:00 pm Lunch and Learn Workshops aim is to identify sets of biomarkers that could be rapidly determined for near-real-time
(Sponsorship Available) or Lunch on Your Own assessment of patient status.
MODELS TO PREDICT RESPONSES 3:00 Networking Refreshment Break, Poster and Exhibit Viewing
1:25 pm Chairperson’s Remarks
1:30 Response Markers to Imatinib Mesylate in the Treatment of
Gastrointestinal Stromal Tumor
Andrew Godwin, M.D., Member, Director, Clinical Molecular Genetics
Laboratory; Director, Biosample Repository, Medical Oncology, Fox Chase
Toxicology Research, FDA
STABILITY AND STANDARDIZATION Evidence indicates that there are sex-related diﬀerences in cardiovascular disease and heart
failure in humans, including age of onset, initial manifestations, and drug responses. These
3:45 Pathogen Surveillance and
diﬀerences may be reﬂective of diﬀerential gene and protein expression. Gene expression
Discovery in Acute and Chronic Disease
proﬁles in the heart were examined in both male and female rats at three diﬀerent ages.
W. Ian Lipkin, M.D., John Snow Professor of The sex diﬀerence was much greater at 21 weeks compared to 8 weeks and 78 weeks. Few
Epidemiology, Professor of Neurology and Pathology , Columbia University common diﬀerentially expressed genes at diﬀerent ages indicated that the sex diﬀerence
Advances in nucleic acid technologies have revolutionized microbiology by facilitating rapid, is age-speciﬁc. These results may provide insights into sex- or age-related cardiovascular
sensitive pathogen surveillance and diﬀerential diagnosis of infectious diseases. Implemen- diseases and drug responses.
tation of these technologies will enable eﬀective intervention and reveal unappreciated links 10:00 Solution Showcase (Sponsorship Available)
between infection and chronic diseases. I will review various assay platforms and describe a
staged strategy for microbiological-diagnostics. 10:15 Coﬀee Break in the Exhibit Hall
11:00 Challenges to Patenting Microarray Inventions
Les Overman , Ph.D., Attorney, Patent & Trademark , Heller Ehrman LLP
4:15 Cytogenetic Stability and Molecular Proﬁling of Clinical Stem Current USPTO practices and new and proposed rules, recent court decisions, and pend-
Cell Products ing legislation are conspiring to make the process of securing and defending patent rights
Robert Deans, Ph.D., Senior Vice President, Regenerative Medicine, much more challenging now and in the future. The business of Microarray technology is
particularly sensitive to these legal changes. Scientists need to know how these changes
Athersys, Inc . will aﬀect research activities and business developers need to know how these changes will
Production of adult stem cells for clinical use requires extensive safety testing, and dem-
aﬀect ﬁnancing, licensing and litigation risk. This presentation will address these concerns
onstration that biological potency is retained over signiﬁcant population doublings in
for stakeholders in the Microarray technology area.
expansion. We have utilized chromosomal SNP analysis to augment karyotypic stability
measurements, and transcriptional proﬁling and gene methylation analysis to demonstrate 11:30 Programmable Submicrolitre Lab-on-a-Chip for Molecular
equivalency of early and late expansion products. Use of diﬀerential proﬁling strategies Diagnostic Applications
has allowed discovery of novel marker sets which distinguish primitive from more mature
adult stem cell types. Stefan Thalhammer, Ph.D., Institute of Radiation Protection, GSF - National
Research Center for Environment and Health
4:45 Standardisation and External Quality Controls for Gene Here we present an acoustic driven free programmable multifunctional biochemical lab-
Expression Measurements in the Clinic: Lessons from BCR ABL on-a-chip. By combining diﬀerent platform elements, like microdissection-, nanoﬂuidic-
and detection-modules, the lab-on-a-chip can be adapted to question- and patient-speciﬁc
Dosage in the Tyrosine Kinase Inhibitors Era
cytogenetic and forensic applications. In contrast to many common available lab-on-a-chip
Jean Gabert, Professor, M.D., Ph.D., Biochemistry & Molecular Biology, approaches, the ﬂuidic handling is done on a planar surface of the lab-on-a-chip. Minute
University Hospital, Marseille amounts of biochemical ﬂuids are conﬁned in ‘virtual’ reaction chambers and ‘virtual’ test
Standardisation and external quality controls are part of the routine in clini- tubes in the form of free droplets. The droplets, ﬂuidic tracks and reaction sites are de-
cal biochemistry since years. International standards and external quality con- ﬁned at the chip surface by a monolayer chemical modiﬁcation of the chip surface. Surface
trol rounds are absolutely warranted for any new biological marker for its world- acoustic waves are employed to agitate and actuate these little virtual test tubes along
wide use in the clinic. Taking the measurement of BCR ABL transcripts (M-BCR) as predetermined trajectories. Well-deﬁned analyses, controlled in the submicrolitre regime,
a model, we developed freeze dried cells that can be sent worldwide at room tem- can be quickly and gently conducted on the lab-on-a-chip
perature. During, the meeting will be reported our eﬀorts in this ﬁeld at the regional,
national and international levels. 12:00 pm Simultaneous Detection and Deﬁnitive Identiﬁcation of Up-
per Respiratory Pathogens Using Resequencing Microarrays
5:15 Reception in the Exhibit Hall
Matthew Lorence, Ph.D., Vice President, Marketing and Sales,
6:30 End of Day Tessarae, LLC
TessArae’s Resequencing Pathogen Microarray (RPM) simultaneously detects and identiﬁes
TUESDAY, MAY 20 hundreds of strains of viral and bacterial pathogens.
Unlike PCR and immunoassays that employ a surrogate marker for detection (e.g. ﬂuo-
7:45 am - 6:00 pm Registration Open rescent signal), RPM results are the nucleotide sequences of pathogen-speciﬁc signatures
7:45 Morning Coﬀee or Breakfast Workshop (Sponsorship Available) that distinguish between known and previously unknown variants, as well as detecting co-
APPLIED MICROARRAYS Epidemiological analysis of such sequence variants enables monitoring of newly intro-
duced, circulating, and commensal organisms within deﬁned populations. A clinical study
of 424 respiratory specimens demonstrated superior sensitivity and speciﬁcity, with zero
8:25 Chairperson’s Remarks false positives, compared to benchmark microbial cultures and PCR tests and identiﬁed
8:30 Genomewide Dissection and Predictive Modeling of thirteen novel H3N2 inﬂuenza strains. RPM provides single-specimen, single-test, same-
Complex Traits day results for real-time global epidemiology.
Marco F. Ramoni , Ph.D., Assistant Professor, Division of Health Sciences 12:30 End of Conference
and Technology Harvard Medical School and Massachusetts Institute of
Technology Media Partners:
Complex traits are the result of the interaction of multiple genetic factors. Genomewide
association studies give us the opportunity to query virtually all of the variations in an
individual, but our analytical methods focus on analyzing one SNP at a time. Learn how to
identify the complex multigenic proﬁles underpinning two common diseases - stroke and
asthma - and to develop prognostic models able predict the risk of an individual based on
his genetic variations.
9:00 Genotyping of Pooled DNA on Aﬀymetrix Microarrays
Tomas Drgon , Ph.D., Staff Fellow, Molecular Neurobiology , NIDA, NIH
I will discuss advantages and disadvantages of pooled DNA genotyping in clinical and basic
research in human genetics. I will discuss the sources of error, from clinical ascertainment,
to pool construction, analysis and replication. I will also discuss selected methods for analy-
sis of pooled genotype data such as Principal Component Analysis, Hierarchical Clustering
and Monte Carlo modeling.
9:30 Analysis of Sex- and Age-Related Diﬀerences in Heart of Rat
Strain Fisher 344 Using Oligonucleotide Microarrays
Tao Han, Ph.D., Staff Scientist, Systems Toxicology, National Center for
Summit – At – A – Glance Sponsorship & Exhibit
Microarrays in Proteomic
7:00 am – 6:00 pm Registration Open Custom designed sponsorship programs enable you to com-
petitively position your company as a leader in the industry,
8:10 – 9:40 Keynote Presentations while collecting quality leads. Sponsored presentations al-
9:40 – 10:25 Grand Opening Coffee Break in Exhibit Hall low your company to educate leading scientiﬁc and execu-
Monday, May 19
10:25 – 12:00 Data Analysis Optimization tive decision-makers on your latest technology or solution.
Luncheon Technology Workshops Sponsorships Include:
12:00 – 1:25
(Sponsorship Available) Embedded Agenda Presentation – Speak to a captive
Models to Predict audience! This Sponsorship includes a podium presenta-
1:25 – 3:00 Biomarkers
Responses tion given during the scientiﬁc agenda, onsite branding,
3:00 – 3:45 Networking Refreshment Break cooperative marketing eﬀorts, and more.
Stability and Breakfast or Luncheon Workshop - These workshops
3:45 – 5:15 Protein Analysis
Standardization include presentation time with a Q&A session over break-
5:15 – 6:30 Reception in Exhibit Hall fast or lunch. CHI will provide the room and AV and will
7:45 am – 6:00 pm Registration Open promote workshop attendance onsite.
8:30 – 10:15 Applied Microarrays Morning Session CHI can also work with you to customize an Invitation-Only
10:15 – 11:00 Networking Coffee Break VIP Dinner, or Networking Reception. Please call for details.
Tuesday, May 20
11:00 – 12:35 Data Analysis Tissue Proteomics
12:35 End of Conferences
Genomic Sample Proteomic Tools for WHY EXHIBIT?
• Demonstrate your expertise to top decision-makers
1 pm – 1:55 pm Registration Open
representing biotech, academic research institutions,
1:55 – 3:30 Isolation Protein Microarrays
national labs, and clinical research organizations.
3:30 – 4:15 Networking Refreshment Break
• Dedicated time from the conference program for del-
4:15 – 6:00 Ampliﬁcation Proteomics as a Tool
egates to view posters and exhibits.
6:00 End of Conference Day
• Market your technology/products/services to all delegates.
7:30 am Morning Coffee
8:30 – 10:00 Keynote Presentations • Identify new business leads.
10:00 – 10:45 Coffee Break in Exhibit Hall • Perfect platform to introduce a new product.
Wednesday, May 21
10:45 – 12:10 Morning Session Morning Session • The Exhibit Hall is strategically located near the session
12:15 – 1:30 Luncheon in Exhibit Hall, sponsored by CHI rooms to allow delegates to easily view your
demonstration and meet you face-to-face.
1:30 – 2:30
2:30-3:00 Networking Refreshment Break
For sponsorship and exhibit details,
3:00 – 5:00 Protein Analysis contact Suzanne Carroll at 781-972-5452
5:00 End of GOT Summit
Hotel & Travel
Hilton Boston Logan Airport
One Hotel Drive
Boston, MA 02128
Tel: 617-568-6700 Flight Discounts:
Fax: 617-568-6800 To receive a 5% discount on American Airlines, American Eagle
Discounted Room Rate: $209 s/d and American Connections call and make your ﬂight reservations
Reduced Room Rate Cut-oﬀ Date: April 21, 2008 at 1-800-433-1790. Please refer to the authorization number
To make hotel reservations: AN# A2418SS.
To book your room online please visit our website and click on the hotel
and travel page or you may call the hotel directly to make your room res- Car Rental Discounts:
ervation.Identify yourself as a Cambridge Healthtech Institute conference Special discount rentals have been established with AVIS for this
attendee to receive the reduced room rate. Reservations made after the conference. You can book your rental online by visiting our website
cut-oﬀ date or after the group room block has been ﬁlled (whichever comes hotel and travel page or by calling AVIS directly at 800-331-1600 and
ﬁrst) will be accepted on a space-and-rate-availability basis. Rooms are lim- referencing our Avis Worldwide Discount (AWD) Number J868190.
ited, so please book early.
Yes! I would like to receive a
FREE eNewsletter subscription to:
Ninth Annual ❒
Microarrays in Medicine The latest industry news, commentary
and highlights from Bio•IT World
Optimizing Diagnostics and Therapeutics The premier e-news source on
technology for healthcare
May 19-20, 2008 • Hilton Boston Logan Airport • Boston, MA
Innovative management in clinical trials
To Register Web: GOTSummit.com Phone: 781-972-5400 OR toll-free in the U.S. 888-999-6288 8563 F
Fax: 781-972-5425 Mail: 250 First Avenue, Suite 300, Needham, MA 02494 USA
REGISTRATION INFORMATION REGISTER 3 — 4th IS FREE
❒ Mr. ❒ Ms. ❒ Mrs. ❒ Dr. ❒ Prof. Individuals must register for the same conference or conference combination and submit completed Present a Poster and Save $50!
Name registration forms together for discount to apply. Please reproduce this registration form as needed
Job Title Div./Dept. Cambridge Healthtech Institute encourages
attendees to gain further exposure by presenting
their work in the poster sessions.
Address To secure a poster board and inclusion in the
City/State/Postal Code conference CD, your abstract must be submitted,
accepted and registration paid in full by
April 28, 2008. Register online to use the
Telephone Poster Abstract Submission form or, if you register
Would you like to receive event updates via fax? ❒ Yes ❒ No Fax by phone, fax, or mail, you will receive Poster
Abstract Submission guidelines via email.
I am interested in presenting a poster at
*Email is not a mandatory ﬁeld. However, by excluding your email you will not receive notiﬁcation about online access to
pre-conference presenter materials, conference updates, networking opportunities and requested eNewsletters. ❒ Microarrays in Medicine
and will submit a completed one-page abstract by
PRICING INFORMATION: April 28, 2008 (Please Note: Registration must be
PREMIUM Attend the ENTIRE GOT Summit (May 19-21) paid in full to present poster.)
Commercial Academic, Government, Title
Advanced Registration until April 11, 2008 ❒ $1745 ❒ $875
Registration after April 11, 2008 and Onsite ❒ $1995
Value! ❒ $995
CHI Insight Pharma Reports
Please select the conference combination you will attend:
A series of reports that evaluate the salient trends in pharmaceu-
❒ Microarrays in Medicine AND Genomic Sample Preparation tical technology, business, and therapy markets. Keep abreast
❒ Microarrays in Medicine AND Proteomic Tools for Diagnostics of the latest advances in pharmaceutical R&D, their potential
❒ Proteomic Sample Preparation AND Genomic Sample Preparation applications and business impacts, and their current and future
❒ Proteomic Sample Preparation AND Proteomic Tools for Diagnostics position in the marketplace.
For a list of reports, visit InsightPharmaReports.com, or
contact Rose LaRaia, firstname.lastname@example.org, 781-972-5444
STANDARD Attend one conference ONLY
Commercial Academic, Government, Additional Registration Details
Each registration includes all conference sessions, posters and
Hospital-Afﬁliated exhibits, food functions, and a copy of the conference CD.
Advanced Registration until April 11, 2008 ❒ $1245 ❒ $645
Registration after April 11, 2008 and Onsite ❒ $1495 ❒ $745 Group Discounts
Special rates are available for multiple attendees from the same
organization. Contact David Cunningham at 781-972-5472 to
Please select the single conference you will attend: discuss your options and take advantage of the savings.
❒ Microarrays in Medicine (May 19-20)
❒ Proteomic Sample Preparation (May 19-20) Handicapped Equal Access
❒ Genomic Sample Preparation (May 20-21) In accordance with the ADA, Cambridge Healthtech Institute is
❒ Proteomic Tools for Diagnostics (May 20-21) pleased to arrange special accommodations for attendees with
special needs. All requests for such assistance must be submitted
Poster Discount ❒ $50 Off in writing to CHI at least 30 days prior to the start of the meeting.
❒ I cannot attend but would like to purchase the entire GOT Summit CD for $750 (plus shipping). In the event that you need to cancel a registration, you may:
Massachusetts delivery will include 5% sales tax. Transfer your registration to a colleague within your organiza-
❒ I cannot attend but would like to purchase the Microarrays in Medicine CD for $250 (plus shipping). tion, credit your registration to another Cambridge Healthtech
Massachusetts delivery will include 5% sales tax. request a refund minus a $100 processing fee per conference.
❒ Please send information on exhibiting and opportunities to present workshops. Request a refund minus the cost ($250) of ordering a copy of the CD
NOTE: Cancellations will only be accepted up to two
PAYMENT INFORMATION: weeks prior to the conference.
❒ Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.
❒ Invoice me, but reserve my space with credit card information listed below. Program and speakers are subject to change.
Invoices unpaid two weeks prior to conference will be billed to credit card at full registration rate. Invoices must be
Video and or audio recording of any kind is
paid in full and checks received by the deadline date to retain registration discount. If you plan to register on site, prohibited onsite at all CHI events.
please check with CHI beforehand for space availability.
❒ Please charge: ❒ AMEX (15 digits) ❒ Visa (13-16 digits) ❒ MasterCard (16 digits) ❒ Diners Club (14 digits)
Card # Exp. Date
Fax or mail your registration to:
Cardholder’s Address (if different from above)
Cambridge Healthtech Institute
250 First Avenue, Suite 300, Needham, Massachusetts 02494
Country T: 781-972-5400 or
toll-free in the U.S. 888-999-6288
F: 781-972-5425 • www.healthtech.com